Forecast
Period
|
2026-2030
|
Market
Size (2024)
|
USD
8.05 Billion
|
Market
Size (2030)
|
USD
20.07 Billion
|
CAGR
(2025-2030)
|
16.65%
|
Fastest
Growing Segment
|
CRISPR/Cas9
|
Largest
Market
|
North
America
|
Market Overview
Global Genome
Editing Market was valued at USD 8.05 Billion in 2024 and is anticipated to
project impressive growth in the forecast period with a CAGR of 16.65% through
2030. The global genome editing market is undergoing substantial growth, fueled
by cutting-edge technological advancements, significant increases in research
funding, and a broadening of its applications in both healthcare and
agriculture sectors. Despite the market's promising expansion, it faces key
challenges such as off-target effects, ethical dilemmas, and the high cost of
genomic tools and technologies. However, these challenges offer a unique
opportunity for innovation and the potential for market growth through the
development of more precise and cost-effective solutions. As the industry
continues to evolve, ongoing technological breakthroughs and strategic
investments are expected to accelerate the market’s trajectory, reinforcing its
strong growth prospects in the coming years.
Key Market Drivers
Rising Incidence of Genetic
Disorders
The
rising incidence of genetic disorders is a critical driver of the growth of the
global genome editing market, as it directly creates a significant demand for
advanced therapeutic solutions. Genetic disorders, which are increasingly
prevalent worldwide, present a complex challenge for the healthcare sector,
pushing the need for innovative treatments. Genetic disorders and congenital
abnormalities affect approximately 2%-5% of all live births, contribute to up
to 30% of pediatric hospital admissions, and are responsible for nearly 50% of
childhood deaths in industrialized nations. Contrary to common assumptions,
available epidemiological data from many countries in the Eastern Mediterranean
Region (EMR) reveal that congenital and genetically linked disorders are
equally significant in this region, if not more so, compared to their
prevalence in more industrialized countries. This underscores the importance of
addressing genetic health challenges within the EMR, highlighting an emerging
market for targeted medical solutions. Genome editing technologies,
particularly CRISPR-Cas9 and other gene-editing tools, offer transformative
potential in addressing these challenges, thereby fueling the market’s
expansion. The growing number of individuals diagnosed with genetic conditions
such as cystic fibrosis, sickle cell anemia, muscular dystrophy, and various
forms of inherited cancers is expanding the addressable patient population for
genome editing treatments. These disorders, often linked to specific genetic
mutations, present significant challenges to traditional medical approaches,
thereby accelerating the need for alternative therapies. Genome editing
technologies offer a direct approach to altering defective genes, potentially
providing long-term cures or treatments for conditions that previously lacked
effective solutions.
With
the rise in genetic disorders, there has been a clear shift toward personalized
or precision medicine, which aims to tailor treatments based on an individual’s
genetic makeup. Genome editing plays a pivotal role in this evolution by
enabling the modification of specific genes responsible for disease. As the
focus on personalized therapies grows, the demand for genome editing tools and
techniques intensifies, propelling further market growth. The ability to
provide individualized treatments that address the root causes of genetic
disorders is a major selling point for genome editing, offering a competitive
edge in the healthcare industry. Gene therapy, which involves the direct
modification of genes to treat or prevent diseases, is becoming an increasingly
important field in medical research. As the prevalence of genetic disorders
rises, gene therapy is increasingly seen as a viable solution to combat these
conditions. Genome editing technologies provide the precision necessary to
modify genes accurately, ensuring that therapeutic interventions target the
exact genetic mutations causing the disorder. The rising demand for gene
therapies, driven by the increasing incidence of genetic disorders, accelerates
the adoption of genome editing tools in both research and clinical settings,
creating substantial growth opportunities for companies operating in this
space. As the incidence of genetic disorders increases, governments and
regulatory bodies are placing greater emphasis on research and development in
the field of gene editing. This rising focus is translating into more funding
for genomic research initiatives aimed at combating genetic diseases. Moreover,
regulatory frameworks are evolving to address the safety and ethical concerns
surrounding gene editing, which in turn is facilitating the progression of
clinical trials and the eventual commercialization of genome editing therapies.
With increased governmental support and clearer regulations, pharmaceutical
companies and biotech firms are better positioned to invest in genome editing
technologies, leading to growth in the market.
Rising
genetic disorder prevalence drives demand for novel and cost-effective
treatment models, beyond traditional pharmaceutical approaches. Genome editing,
with its potential to correct genetic defects at the DNA level, is seen as a
more targeted and efficient treatment modality compared to conventional methods
like symptom management or gene therapy involving viral vectors. As the market
for these advanced treatments grows, companies that focus on genome editing as
a core part of their strategy stand to benefit from the escalating demand for
new, more effective solutions for genetic disorders. Rising awareness of
genetic disorders, along with advocacy from patient organizations, is further
fueling the demand for genome editing solutions. As more individuals are
diagnosed and educated about their genetic conditions, there is a growing
societal push for viable and effective treatments. Public demand for
breakthroughs in the treatment of genetic diseases encourages research and
development in genome editing, thereby driving market growth. Additionally,
public pressure can accelerate regulatory approvals and reduce time to market
for genome editing therapies.
Increase in Precision Medicine
The
increase in precision medicine is a key driver of growth in the global genome
editing market, as it directly intersects with the capabilities of genome
editing technologies. Precision medicine, which tailors medical treatment to an
individual’s genetic profile, is reshaping the healthcare landscape, and genome
editing plays a pivotal role in its implementation. Precision medicine is
centered around understanding the genetic makeup of individual patients to
create personalized treatment plans. As more focus is placed on genetic
insights, there is a growing demand for interventions that can directly modify
the genetic causes of diseases. Genome editing technologies, such as
CRISPR-Cas9, enable precise alterations to the genome, offering a highly
targeted approach to treating genetic disorders. This demand for personalized
genetic therapies, driven by the broader adoption of precision medicine,
increases the reliance on genome editing tools to provide customized solutions
for individual patients. Precision medicine is gaining significant traction
among start-ups in the life sciences sector, as it is increasingly recognized
as a key component of future healthcare innovations. The approach offers
several compelling advantages, including optimized healthcare resource
utilization, enhanced treatment effectiveness, fewer adverse drug reactions,
and improved patient adherence to treatment regimens. Moreover, precision
medicine has become a central focus in regulatory approvals, accounting for
approximately 35% of FDA approvals annually since 2018, with projections
indicating continued growth in this trend. This rising emphasis on precision
medicine highlights the substantial market opportunity for companies in this
space to capitalize on emerging trends in personalized healthcare.
As
precision medicine advances, the ability to address genetic disorders at their
molecular origin becomes a primary focus. Many genetic diseases, such as sickle
cell anemia, cystic fibrosis, and muscular dystrophy, result from specific
mutations within a patient’s DNA. Traditional treatments often focus on
managing symptoms rather than addressing the root cause of the disease. Genome
editing, by contrast, offers the potential for permanent cures or long-term
management by directly correcting these genetic mutations. As precision
medicine progresses, the need for genome editing technologies to enable these
transformative treatments becomes even more pronounced, thereby driving market
growth.
Precision
medicine relies heavily on genomic sequencing and diagnostics to identify
genetic variants that may contribute to diseases. As the field of genomics
expands, so too does the amount of genetic data available for analysis. Genome
editing technologies are increasingly integrated into these diagnostic
workflows to provide not just identification but actionable solutions to
correct genetic variations. This seamless integration between genomics,
diagnostics, and therapeutic interventions amplifies the demand for genome
editing tools and accelerates their adoption within precision medicine
frameworks. The synergy between these fields results in a more robust and
dynamic healthcare model that directly impacts the growth of the genome editing
market. The expansion of precision medicine has led to a surge in gene therapy
applications, which aim to treat or prevent diseases by modifying genes. Genome
editing is the cornerstone of many gene therapy techniques, providing the
precision necessary to target and edit specific genes associated with diseases.
The ability to perform gene modifications at a highly accurate level is crucial
for the success of gene therapies. As precision medicine progresses toward more
targeted and personalized therapies, the reliance on genome editing
technologies to achieve these outcomes increases. The continued advancement and
application of gene therapies, made possible by genome editing, is therefore a
major factor driving market growth.
The
rise of precision medicine is fostering a new era of clinical research that
focuses on the development of treatments based on individual genetic profiles.
Genome editing plays a central role in this research by enabling the creation
of disease models, studying genetic mutations, and developing therapeutic
interventions tailored to specific patient populations. Clinical trials are
increasingly using genome editing to test the effectiveness of precision
treatments, further driving the demand for these technologies. The success of
these trials and the subsequent approval of gene-edited therapies will
contribute to the growth of the global genome editing market. One of the
promises of precision medicine is its ability to optimize treatment plans for
individuals, reducing unnecessary treatments and improving overall healthcare
outcomes. Genome editing technologies contribute to this cost-effectiveness by
offering targeted, potentially one-time therapies that address the root cause
of diseases. By reducing the need for long-term symptomatic treatment, genome
editing presents a cost-efficient approach to managing genetic diseases. As
healthcare systems worldwide increasingly prioritize cost-effective treatments,
genome editing tools that enable precision medicine will become more integral
to healthcare providers, driving demand and further expanding the market.
Collaborations and Strategic
Partnerships
Collaborations
and strategic partnerships are pivotal drivers of growth in the global genome
editing market, accelerating the development, commercialization, and adoption
of cutting-edge gene-editing technologies. The complexity of genome editing
requires a multidisciplinary approach, combining expertise in molecular
biology, genetics, biotechnology, and clinical applications. Strategic
partnerships foster innovation, provide financial resources, and streamline the
pathway from research to market. Moderna, Inc, a leader in messenger RNA
(mRNA) therapeutics and vaccines, and Life Edit Therapeutics Inc., a subsidiary
of ElevateBio specializing in next-generation gene editing technologies, have
announced a strategic research and development partnership. The collaboration
will leverage Life Edit's proprietary gene editing technologies, including base
editing, alongside Moderna’s mRNA platform to advance in vivo gene editing
therapies targeting specific therapeutic indications. This partnership aims to
explore the potential of mRNA for the precise delivery of gene editing tools,
offering significant promise in addressing rare genetic disorders and other
challenging diseases. Genome editing is a rapidly evolving field, with
continuous advancements required to enhance precision, reduce off-target
effects, and develop new applications. Strategic collaborations between biotech
companies, academic institutions, and research organizations are crucial in
facilitating accelerated R&D. These partnerships pool resources, talent,
and expertise, enabling faster breakthroughs in gene-editing technologies.
Collaborative R&D efforts allow for the sharing of knowledge, technology, and
infrastructure, thus improving the pace of innovation. This expedited
development is essential for keeping up with growing market demands and
positioning companies as leaders in the competitive genome editing market.
Genome
editing technologies require substantial investment in research, development,
and clinical trials. Through strategic partnerships with venture capitalists,
pharmaceutical companies, and academic institutions, genome editing firms gain
access to critical financial resources and infrastructure. Collaborations with
established pharmaceutical companies, for example, provide smaller biotech
firms with the capital and facilities needed to scale up production, conduct
clinical trials, and meet regulatory requirements. This influx of funding helps
genome editing companies move from laboratory innovations to commercially
viable products, thus expanding the market. Additionally, financial backing
allows firms to overcome the high costs associated with genome editing research
and development. Collaborations with regulatory bodies, industry leaders, and
global research networks can help streamline the regulatory approval process
for genome editing technologies. Strategic partnerships often involve sharing
clinical data, results from preclinical studies, and expertise on regulatory
compliance, which can expedite the approval process for gene-editing therapies.
Partnering with established pharmaceutical or medical companies that have deep
experience navigating regulatory environments can help new players in the
genome editing market ensure that their products meet regulatory standards more
efficiently. This collaboration not only accelerates time-to-market for genome
editing treatments but also reduces the risks associated with navigating
complex regulatory landscapes independently. Strategic alliances with global
players, such as multinational pharmaceutical companies and medical device
manufacturers, significantly expand the market reach and distribution channels
for genome editing technologies. These partnerships allow genome editing
companies to leverage the extensive networks, sales teams, and global market
penetration of larger, established firms. By collaborating with industry
giants, genome editing companies gain access to a wider customer base,
including hospitals, research institutions, and biotechnology firms across
different regions. As the global demand for genome editing solutions continues
to rise, these collaborations enable faster market entry and broader
commercialization of gene-editing products, thus driving overall market growth.
One
of the most promising outcomes of collaborations in the genome editing space is
the co-development of novel therapeutics. Strategic partnerships between
biotech companies and pharmaceutical firms can combine the strengths of both
parties—such as genome editing expertise and a strong drug development
pipeline. These partnerships often focus on the development of gene therapies
for genetic diseases, where genome editing plays a critical role in modifying
the DNA of patients to cure or manage disease. By joining forces, these
companies can share the financial burden of clinical trials, reduce risks, and
increase the likelihood of bringing new, life-changing therapies to market. The
increasing number of gene therapies under development in collaboration with
large pharmaceutical companies is significantly driving the growth of the
genome editing market. In an industry as dynamic as genome editing, access to
proprietary technologies and intellectual property (IP) is crucial for
maintaining a competitive advantage. Collaborations with leading academic
institutions or other research organizations provide genome editing companies
with access to cutting-edge research, patented technologies, and new
gene-editing tools. For example, partnerships with universities or renowned
biotech firms allow access to novel genome editing technologies, such as the
next-generation CRISPR systems, which can improve the precision and efficiency
of gene modification. By acquiring or licensing these technologies through
collaborations, companies can enhance their product offerings and stay ahead of
competitors, thereby driving growth and innovation within the genome editing
market.

Download Free Sample Report
Key Market Challenges
Technical Limitations and
Off-Target Effects
One
of the primary challenges facing the genome editing market is the technical
limitations of current gene-editing tools, particularly off-target effects.
While technologies such as CRISPR-Cas9 have revolutionized the field, their
accuracy remains a concern. Off-target effects refer to unintended changes in
the genome, which could result in harmful or unpredictable outcomes. These
inaccuracies raise safety concerns, especially in clinical applications where
precision is paramount. For example, gene therapies aimed at treating genetic
disorders could inadvertently cause other mutations, leading to unforeseen
consequences. The lack of consistency and precision in genome editing tools
limits their widespread use in therapeutic applications, particularly in human
clinical trials. Overcoming these technical challenges requires further
research, innovation, and refinement of gene-editing technologies, which can
delay market adoption and hinder growth.
Regulatory and Ethical
Barriers
The
regulatory landscape surrounding genome editing is complex and varies
significantly across regions, creating barriers to market entry and expansion.
Regulatory bodies such as the FDA and EMA have stringent approval processes for
gene-editing therapies, which often require extensive preclinical and clinical
trials to ensure safety and efficacy. The long timelines and high costs
associated with regulatory approval can slow down the commercialization of
genome-editing-based treatments. Additionally, the ethical implications of gene
editing, particularly in human germline editing, remain a significant concern.
Modifying the genetic makeup of embryos or germline cells raises ethical
questions about the potential for misuse, unintended consequences, and societal
impacts. These ethical dilemmas, along with evolving regulatory frameworks that
are still adapting to new gene-editing technologies, pose a challenge to
industry growth. Companies must navigate these regulatory complexities and
address public concerns to ensure successful product development and approval.
Key Market Trends
Integration of Artificial
Intelligence and Machine Learning
The
integration of artificial intelligence (AI) and machine learning (ML) with
genome editing technologies is a transformative trend that is accelerating the
development of more precise and efficient gene-editing tools. AI and ML
algorithms can analyze vast amounts of genomic data, identify patterns, and
predict the outcomes of gene edits, which significantly enhances the accuracy
of genome editing. These technologies are particularly useful in identifying
potential off-target effects and improving the overall efficiency of
gene-editing processes. By reducing errors and optimizing editing techniques,
AI and ML are helping researchers design more precise and reliable
genome-editing strategies. The growing application of AI in genome editing not
only improves the quality of gene therapies but also shortens development
timelines, driving future growth in the market. As these technologies evolve,
they will further transform how genome editing is utilized across therapeutic
and agricultural applications.
Expansion of Gene Therapy and
Personalized Medicine
A
key trend that is accelerating the future growth of the genome editing market
is the increasing adoption of gene therapy and personalized medicine. Gene
therapy, which uses genome-editing technologies to modify genes in order to
treat or cure genetic disorders, is quickly becoming a mainstream approach in
the treatment of various diseases. As the medical community moves toward
personalized medicine—where treatments are tailored to an individual's genetic
profile—genome editing plays a critical role in enabling highly specific and
effective therapies. This shift toward personalized approaches is particularly
relevant for diseases with a strong genetic basis, such as inherited disorders,
cancers, and neurological conditions. The ability to edit genes in patients’
cells to address the root causes of these diseases is driving demand for
genome-editing solutions. As regulatory approvals for gene therapies continue
to expand and success stories of gene-edited treatments emerge, the market for
genome editing is expected to experience rapid growth, with gene therapy
becoming a cornerstone of modern healthcare.
Segmental Insights
Technology Insights
Based
on the category of Technology, the CRISPR/Cas9 segment emerged as the dominant
in the global market for Genome Editing in 2024. The key reasons CRISPR/Cas9
has become the dominant technology in genome editing is its unparalleled
precision and efficiency compared to earlier methods, such as zinc-finger
nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs).
CRISPR/Cas9 uses a guide RNA to direct the Cas9 enzyme to a specific location
in the DNA sequence, where it induces a targeted cut. This simplicity in design
allows researchers to modify specific genes with high accuracy, reducing the
likelihood of off-target effects that can occur with older technologies. The
efficiency of CRISPR/Cas9 not only speeds up the process of genetic
modification but also lowers the cost and resources required, making it the
preferred method for both academic research and clinical applications.
CRISPR/Cas9's
dominance in the global genome editing market is also attributed to its broad
applicability in healthcare and therapeutic development. Gene editing has
gained significant momentum in the field of gene therapy, particularly in the
treatment of genetic disorders, cancers, and other complex diseases.
CRISPR/Cas9 enables the precise modification of disease-causing genes, offering
the potential to cure or manage conditions that were previously considered
incurable, such as sickle cell anemia, muscular dystrophy, and cystic fibrosis.
The technology’s ability to target and edit specific genes within a patient’s
cells is driving its widespread adoption in clinical research, making it a
central focus of gene-editing-based therapies. The growing success of clinical
trials and the increasing number of regulatory approvals for CRISPR/Cas9-based
treatments further bolster its dominance in the healthcare segment, providing a
strong foundation for continued market growth. CRISPR/Cas9 technology offers
significant cost advantages over older genome-editing tools. Traditional
methods, such as ZFNs and TALENs, are complex, time-consuming, and expensive,
requiring the production of custom proteins for each target gene. In contrast,
CRISPR/Cas9 uses RNA molecules to guide the Cas9 enzyme to the target gene,
significantly simplifying the process and reducing production costs. The
scalability of CRISPR/Cas9 also contributes to its market dominance. The
technology is adaptable to high-throughput applications, such as screening
large gene libraries or conducting genome-wide association studies, making it
suitable for both academic research and large-scale commercial applications.
This affordability and scalability enable widespread adoption, especially among
biotech startups, academic institutions, and research organizations with
limited budgets, further cementing CRISPR/Cas9's market leadership. These
factors collectively contribute to the growth of this segment.
Delivery Mode Insights
Based
on the category of Delivery Mode, the Ex-Vivo segment emerged as the dominant
in the global market for Genome Editing in 2024. Ex-vivo gene editing offers
greater precision and control over the editing process, which is one of the
primary reasons it dominates the market. In this approach, cells are harvested
from the patient, edited in the laboratory, and then reintroduced after the
modifications are complete. This process allows researchers and clinicians to
closely monitor the genetic changes, ensuring that only the intended edits are
made. Unlike in vivo techniques, where editing occurs inside the patient’s
body, ex-vivo gene editing can minimize the risk of off-target effects and
unintended mutations. The ability to conduct these procedures in controlled
laboratory environments adds a layer of assurance in terms of safety and
accuracy, which is especially crucial in therapeutic settings.
The
success of ex-vivo gene editing in clinical trials has been a significant
driver of its dominance in the market. Several gene-editing therapies, such as
those aimed at treating genetic blood disorders like sickle cell anemia and
beta-thalassemia, have relied on ex-vivo techniques to modify the patient's own
hematopoietic stem cells (HSCs) before reintroducing them into the body. For
instance, therapies such as Kymriah and Yescarta, which involve the
modification of immune cells to fight cancer, have used ex-vivo gene editing
successfully, leading to groundbreaking results and regulatory approvals. These
proven successes have helped build confidence in the efficacy and safety of
ex-vivo gene editing, attracting significant investment and encouraging the
market’s expansion. The track record of ex-vivo approaches in clinical
applications has set a strong precedent, propelling it as the dominant mode of
delivery in therapeutic gene editing. Ex-vivo genome editing allows for a
reduced risk of immune rejection compared to in-vivo methods. When editing
cells outside the body, clinicians can select the best candidates for
reintegration, ensuring the cells are compatible with the patient’s immune
system. This process of selecting, editing, and reintroducing the patient’s own
cells minimizes the risk of the body’s immune system rejecting the edited
cells, which is a concern in in-vivo editing approaches where foreign genetic
material might be introduced. For instance, in ex-vivo approaches involving the
re-engineering of immune cells, such as in CAR-T cell therapy, the cells are
often derived from the patient’s own body, further reducing the likelihood of
adverse immune responses. This compatibility makes ex-vivo a safer and more
reliable choice for personalized medicine applications, particularly in immune
therapies and genetic disorder treatments.

Download Free Sample Report
Regional Insights
North
America emerged as the dominant in the global Genome Editing market in 2024,
holding the largest market share in terms of value. North America boasts one of
the most advanced research and development (R&D) ecosystems in the world,
which has been instrumental in positioning the region at the forefront of the
genome editing market. Leading academic institutions, such as Harvard University,
MIT, and Stanford University, along with a high concentration of specialized
research centers, have been driving innovation in genome editing technologies
like CRISPR/Cas9 and TALENs. These institutions consistently produce
cutting-edge research, attract top talent, and collaborate with private sector
players, thereby accelerating the development and application of genome-editing
tools. Additionally, North American countries, particularly the United States
and Canada, invest heavily in biotech and life sciences research, fostering an
environment where genome editing technologies can thrive. North America is home
to many of the world’s leading biotechnology firms, which are driving
commercialization and innovation in the genome editing space. Companies such as
Editas Medicine, CRISPR Therapeutics, Intellia Therapeutics, and Thermo Fisher
Scientific are based in the region and are actively involved in advancing
genome editing technologies for therapeutic, agricultural, and industrial
applications. These companies have secured significant investments, raised
capital through public offerings, and formed strategic partnerships to
accelerate the development of gene-editing products. The strong presence of
these firms not only contributes to the region's market dominance but also
provides a foundation for the continuous growth and expansion of the genome
editing market in North America.
Recent Developments
- In
January 2024- The Innovative Genomics Institute (IGI) and Danaher Corporation
have announced a strategic collaboration aimed at accelerating and scaling the
development of CRISPR-based therapeutic solutions. This partnership combines
the expertise of IGI, a leader in genome editing research, with Danaher's
cutting-edge technological platforms, to enhance the pace of CRISPR
gene-editing therapies. The collaboration will focus on advancing the
development of CRISPR cures for genetic disorders and other diseases by leveraging
Danaher's state-of-the-art tools and IGI's pioneering research in genome
editing.
- In
June 2024, A research team at the Center for Advanced Bioenergy and Bioproducts
Innovation (CABBI) has successfully applied CRISPR/Cas9 gene-editing technology
to optimize the leaf angle in sugarcane, resulting in enhanced sunlight capture
and increased biomass production. This innovation represents a significant
advancement in crop optimization, positioning sugarcane as a more efficient
source of bioenergy. Similarly, scientists have leveraged CRISPR/Cas9 to
enhance gene expression in rice by modifying its upstream regulatory DNA,
driving improvements in crop yields and overall agricultural productivity.
These breakthroughs underscore the potential of CRISPR technology in
transforming agricultural practices and boosting the efficiency of key staple
crops.
- In
March 2024, The approval of Casgevy in late 2023 marks a groundbreaking
achievement in the field of CRISPR-based therapies, as it becomes the
first-ever CRISPR-derived medicine approved for clinical use. Casgevy, a
transformative treatment for sickle cell disease (SCD) and transfusion-dependent
beta thalassemia (TDT), has the potential to redefine the standard of care for
these genetic blood disorders. The Innovative Genomics Institute (IGI) has
closely monitored the progress of CRISPR clinical trials since their inception,
and while this milestone has long been anticipated, the speed at which it has
been achieved underscores the rapid advancements being made in gene-editing
technologies. This approval sets a significant precedent, accelerating the
pathway for further CRISPR-based therapeutic solutions in the near future.
- In
May 2024, AstraZeneca successfully concluded its equity investment agreement
with Cellectis, a clinical-stage biotechnology company. This investment, along
with the research collaboration agreement announced in November 2023, will
combine AstraZeneca's expertise with Cellectis' proprietary gene-editing
technologies and advanced manufacturing capabilities. The collaboration aims to
design up to 10 innovative cell and gene therapy products targeting areas of
significant unmet medical need, including oncology, immunology, and rare
diseases.
Key Market Players
- Merck
KGaA
- Cibus
Inc.
- Danaher
Corporation
- GenScript
Biotech Corporation
- Thermo
Fisher Scientific Inc
- Lonza
Group Ltd
- Takara
Bio Inc.
- AstraZeneca
- Precision
BioSciences
- Sangamo
Therapeutics, Inc
By
Technology
|
By
Delivery Mode
|
By
Application
|
By
Mode
|
By
End User
|
By
Region
|
- (CRISPR)/Cas9
- TALENs/MegaTALs
- ZFN
- Meganuclease
- Others
|
|
- Genetic
Engineering
- Clinical
Applications
|
|
- Biotechnology
and Pharmaceutical Companies
- Academic
and Government Research Institutes
- Contract
Research Organizations
|
- North
America
- Europe
- Asia
Pacific
- South
America
- Middle
East & Africa
|
Report Scope:
In this report, the Global Genome Editing Market
has been segmented into the following categories, in addition to the industry
trends which have also been detailed below:
- Genome Editing Market, By Technology:
o (CRISPR)/Cas9
o TALENs/MegaTALs
o ZFN
o Meganuclease
o Others
- Genome Editing Market, By Delivery Mode:
o Ex-vivo
o In-vivo
- Genome Editing Market, By Application:
o Genetic Engineering
o Clinical Applications
- Genome Editing Market, By Mode:
o Contract
o In-house
- Genome Editing Market, By End User:
o Biotechnology and Pharmaceutical
Companies
o Academic and Government
Research Institutes
o Contract Research Organizations
- Genome Editing Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Genome
Editing Market.
Available Customizations:
Global Genome Editing market report with the
given market data, TechSci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Global Genome Editing
Market is an upcoming report to be released soon. If you wish an early delivery
of this report or want to confirm the date of release, please contact us at [email protected]